AU2003277989A1 - Diagnostic assay for measuring a cell mediated immune response - Google Patents
Diagnostic assay for measuring a cell mediated immune response Download PDFInfo
- Publication number
- AU2003277989A1 AU2003277989A1 AU2003277989A AU2003277989A AU2003277989A1 AU 2003277989 A1 AU2003277989 A1 AU 2003277989A1 AU 2003277989 A AU2003277989 A AU 2003277989A AU 2003277989 A AU2003277989 A AU 2003277989A AU 2003277989 A1 AU2003277989 A1 AU 2003277989A1
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- immune
- cells
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000021633 leukocyte mediated immunity Effects 0.000 title claims description 16
- 238000003556 assay Methods 0.000 title description 32
- 238000000034 method Methods 0.000 claims description 127
- 210000004369 blood Anatomy 0.000 claims description 110
- 239000008280 blood Substances 0.000 claims description 110
- 239000000427 antigen Substances 0.000 claims description 108
- 102000036639 antigens Human genes 0.000 claims description 105
- 108091007433 antigens Proteins 0.000 claims description 105
- 239000012642 immune effector Substances 0.000 claims description 61
- 229940121354 immunomodulator Drugs 0.000 claims description 61
- 230000004044 response Effects 0.000 claims description 42
- 239000008121 dextrose Substances 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 30
- 238000011534 incubation Methods 0.000 claims description 28
- 238000002965 ELISA Methods 0.000 claims description 23
- 230000000638 stimulation Effects 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 229960000814 tetanus toxoid Drugs 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 210000000987 immune system Anatomy 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 235000021309 simple sugar Nutrition 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 5
- 230000001885 phytohemagglutinin Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 241000186367 Mycobacterium avium Species 0.000 claims description 3
- 102000007982 Phosphoproteins Human genes 0.000 claims description 3
- 108010089430 Phosphoproteins Proteins 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 239000000523 sample Substances 0.000 description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 239000003226 mitogen Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000975 dye Substances 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000013500 data storage Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 230000003936 working memory Effects 0.000 description 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 description 2
- IKYJCHYORFJFRR-UHFFFAOYSA-N Alexa Fluor 350 Chemical compound O=C1OC=2C=C(N)C(S(O)(=O)=O)=CC=2C(C)=C1CC(=O)ON1C(=O)CCC1=O IKYJCHYORFJFRR-UHFFFAOYSA-N 0.000 description 2
- WEJVZSAYICGDCK-UHFFFAOYSA-N Alexa Fluor 430 Chemical compound CC[NH+](CC)CC.CC1(C)C=C(CS([O-])(=O)=O)C2=CC=3C(C(F)(F)F)=CC(=O)OC=3C=C2N1CCCCCC(=O)ON1C(=O)CCC1=O WEJVZSAYICGDCK-UHFFFAOYSA-N 0.000 description 2
- WHVNXSBKJGAXKU-UHFFFAOYSA-N Alexa Fluor 532 Chemical compound [H+].[H+].CC1(C)C(C)NC(C(=C2OC3=C(C=4C(C(C(C)N=4)(C)C)=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C=C1)=CC=C1C(=O)ON1C(=O)CCC1=O WHVNXSBKJGAXKU-UHFFFAOYSA-N 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000938605 Crocodylia Species 0.000 description 2
- 208000007465 Giant cell arteritis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 101150050192 PIGM gene Proteins 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000007503 antigenic stimulation Effects 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 201000008298 histiocytosis Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000005381 magnetic domain Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 1
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 239000012112 Alexa Fluor 633 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 239000012115 Alexa Fluor 660 Substances 0.000 description 1
- 239000012116 Alexa Fluor 680 Substances 0.000 description 1
- 239000012117 Alexa Fluor 700 Substances 0.000 description 1
- 239000012118 Alexa Fluor 750 Substances 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- 206010004272 Benign hydatidiform mole Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- RURLVUZRUFHCJO-UHFFFAOYSA-N Chromomycin A3 Natural products COC(C1Cc2cc3cc(OC4CC(OC(=O)C)C(OC5CC(O)C(OC)C(C)O5)C(C)O4)c(C)c(O)c3c(O)c2C(=O)C1OC6CC(OC7CC(C)(O)C(OC(=O)C)C(C)O7)C(O)C(C)O6)C(=O)C(O)C(C)O RURLVUZRUFHCJO-UHFFFAOYSA-N 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 206010052465 Congenital poikiloderma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 108091005941 EBFP Proteins 0.000 description 1
- 108091005942 ECFP Proteins 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 102220566467 GDNF family receptor alpha-1_S65A_mutation Human genes 0.000 description 1
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 description 1
- 102220566453 GDNF family receptor alpha-1_Y66F_mutation Human genes 0.000 description 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 description 1
- 102220566455 GDNF family receptor alpha-1_Y66W_mutation Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017918 Gastroenteritis viral Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FGBAVQUHSKYMTC-UHFFFAOYSA-M LDS 751 dye Chemical compound [O-]Cl(=O)(=O)=O.C1=CC2=CC(N(C)C)=CC=C2[N+](CC)=C1C=CC=CC1=CC=C(N(C)C)C=C1 FGBAVQUHSKYMTC-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000004485 Nijmegen breakage syndrome Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 208000000791 Rothmund-Thomson syndrome Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DPXHITFUCHFTKR-UHFFFAOYSA-L To-Pro-1 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 DPXHITFUCHFTKR-UHFFFAOYSA-L 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- MZZINWWGSYUHGU-UHFFFAOYSA-J ToTo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3S2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2S1 MZZINWWGSYUHGU-UHFFFAOYSA-J 0.000 description 1
- 102220615016 Transcription elongation regulator 1_S65C_mutation Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 102000012349 Uroplakins Human genes 0.000 description 1
- 108010061861 Uroplakins Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SUIPVTCEECPFIB-UHFFFAOYSA-N monochlorobimane Chemical compound ClCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O SUIPVTCEECPFIB-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000037830 nasal cancer Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 201000001219 parotid gland cancer Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000006402 rhabdoid cancer Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102200089551 rs5030826 Human genes 0.000 description 1
- 230000036185 rubor Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
WO 2004/042396 PCT/AU2003/001464 -1 DIAGNOSTIC ASSAY FOR MEASURING A CELL MEDIATED IMMUNE RESPONSE BACKGROUND OF THE INVENTION 5 FIELD OF THE INVENTION The present invention relates generally to a diagnostic. assay and, more particularly, an assay for measuring cell-mediated immune reactivity. Even more particularly, the present invention provides an assay and a kit for measuring a cell-mediated response to an antigen 10 using whole blood or other suitable biological sample. The assay may be conducted using ligands to immune effector molecules or at the nucleic acid level, screening for expression of genes encoding the immune effector molecules. The assay is useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications. 15 DESCRIPTION OF THE PRIOR ART Bibliographic details of references provided in the subject specification are listed at the end of the specification. 20 Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country. Measurement of cell-mediated immune (CMI) responses is important for immune 25 diagnosis of many infectious and autoimmune diseases, as a marker for immunocompetence, and for detection of T-cell responses to endogenous and exogenous antigens (i.e. vaccines). Current methods for detecting CMI responses include skin tests measuring both immediate 30 and delayed type hypersensitivity, lymphocyte proliferation assays and measurement of cytokines produced by purified mononuclear cells cultured with antigen.
WO 2004/042396 PCT/AU2003/001464 -2 Most in vitro methods for detecting CMI responses involve the purification of lymphocytes from whole blood, culturing these lymphocytes with an antigen for periods from 12 hours to 6 days and then detecting T-cell reactivity to the antigen. Older, established methods, 5 such as the proliferation assay, use the uptake of radioactive isotopes by dividing T-cells as a marker for CMI reactivity. More recently, techniques such as a single cell assay (ELISpot) have been used to detect the number of T-cells producing certain cytokines in response to the antigenic stimulation. 10 Despite the existence of the previously used assays for measuring CMI responsiveness, the practical limitations of easily and accurately measuring CMI responses have hitherto precluded large scale adoption of these assays in standard and routine medical practice in the diagnosis of infectious disease, autoimmune disease and oncology.
WO 2004/042396 PCT/AU2003/001464 -3 SUMMARY OF THE INVENTION Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the 5 inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. The present invention provides a method for measuring CMI in a subject by incubating a sample from the subject which comprises T-cells or other cells of the immune system with 10 an antigen. Production of IFN-7y or other cytokine or immune effector molecule(s) is then detected. The presence or level of immune effector is then indicative of the level of cell mediated responsiveness of the subject. Preferably, the sample is whole blood which is collected in a suitable container comprising 15 the antigen. Optionally, a simple sugar such as dextrose is added to the incubation mixture. Accordingly, one aspect of the present invention contemplates a method for measuring a CMI response in a subject, said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing 20 immune effector molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell-mediated immune response. 25 Preferably, the subject is a human. The present invention contemplates, however, primates, livestock animals, laboratory test animals, companion animals and avian species as well as non-mammalian animals such as reptiles and amphibians. The assay has applications, therefore, in human, livestock, veterinary and wild life therapy and diagnosis. 30 In a preferred embodiment, the sample is whole blood which is collected in collection tubes containing the antigen or to which the antigen is added. Generally, blood is WO 2004/042396 PCT/AU2003/001464 -4 maintained in the presence of heparin. Heparin may be in the tube when blood is added or is added subsequently. The use of blood collection tubes is compatible with standard automated laboratory systems and these are amenable to analysis in large-scale and random access sampling. Blood collection tubes also minimize handling costs and reduces 5 laboratory exposure to whole blood and plasma and, hence, reduces the risk of laboratory personnel from contracting a pathogenic agent such as human immunodeficiency virus HIV or hepatitis B virus (HBV). Furthermore, use of the collection tubes to conduct the incubation renders the assay far more sensitive than the previously used 24 well culture well plates. 10 The present invention provides an enhanced CMI assay, therefore, comprising use of a collection tube, optionally a simple sugar such as dextrose and the incubation step. The incubation step is preferably from 5 to 50 hours. 15 The immune effector molecule is preferably a cytokine such as but not limited to IFN-y. The presence or level of immune effector may be determined at the level of the molecule itself or to the extent to which a gene is expressed. The present invention further provides kits comprising reagents and compartments 20 required to perform the assay. Generally, the kit further comprises a set of instructions. The assay may also be automated or semi-automated and the automated aspects may be controlled by computer software. 25 The present invention still further contemplates a method of treatment of a pathological condition such as infection by a microorganism, parasite or virus, an autoimmune condition or cancer. The method comprises assessing the capacity of a subject to mount a cell-mediated immune response and then selecting a therapeutic protocol such as inducing CMI against a target antigen alone or in combination with other therapy. 30 WO 2004/042396 PCT/AU2003/001464 -5 A list of abbreviations used herein is provided in Table 1. TABLE 1 Abbreviations ABBREVIATION DESCRIPTION CMI cell-mediated immunity CSF colony stimulating factor ELISA enzyme linked immunosorbent assay ELISpot single cell ELISA G-CSF granulocyte-CSF GM-CSF granulocyte, macrophage-CSF HB3V hepatitis B virus HIV human immunodeficiency virus IFN-y interferon-gamma PPD Mycobacterium-tuberculosis purified protein derivative TNF-a tumor necrosis factor 5 WO 2004/042396 PCT/AU2003/001464 -6 BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a diagrammatic representation of a system used to carry out the instructions encoded by the storage medium. 5 Figure 2 is a diagrammatic representation of a cross-section of a magnetic storage medium. Figure 3 is a diagrammatic representation of a cross-section of an optically readable data 10 storage system.
WO 2004/042396 PCT/AU2003/001464 -7 DETAILED DESCRIPTION OF THE INVENTION The present invention provides an assay of the potential or capacity of a subject to mount a CMI response. The assay is based on measuring immune effector molecule production by 5 cells of the immune system in response to antigenic stimulation. The immune effectors may be detected using ligands such as antibodies specific for the effectors or by measuring the level of expression of genes encoding the effectors. The present invention provides, therefore, a means to determine the responsiveness of CMI in a subject and, in turn, provides a means for the diagnosis of infectious diseases, pathological conditions, level of 10 immunocompetence and a marker of T-cell responsiveness to endogenous or exogenous antigens. Accordingly, one aspect of the present invention contemplates a method for measuring a CMI response in a subject, said method comprising collecting a sample from said subject 15 wherein said sample comprises cells of the immune system which are capable of producing immune effector molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell-mediated immune response. 20 Reference to a "subject" includes a human or non-human species including primates, livestock animals (e.g. sheep, cows, pigs, horses, donkey, goats), laboratory test animals (e.g. mice, rats, rabbits, guinea pigs, hamsterss, companion animals (e.g. dogs, cats), avian species (e.g. poultry birds, aviary birds), reptiles and amphibians. The present invention 25 has applicability, therefore, in human medicine as well as having livestock and veterinary and wild life applications. Most preferably, however, the subject is a human and the CMI response assay has applications in screening for responsiveness to pathogenic microorganisms, viruses and parasites, potential for development or monitoring autoimmune conditions and for monitoring a subject's response to oncological challenge. 30 WO 2004/042396 PCT/AU2003/001464 -8 According to this preferred embodiment, therefore, the present invention provides a method for measuring a CMI response in a human subject, said method comprising collecting a sample from said human subject wherein said sample comprises cells of the immune system which are capable of producing immune effector molecules following 5 stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said human subject to mount a cell-mediated immune response. 10 Reference to "immune cells" includes cells such as lymphocytes including natural killer (NK) cells, T-cells, (CD4 and/or CD8 + cells), B-cells, macrophages and monocytes, dendritic cells or any other cell which is capable of producing an effector molecule in response to direct or indirect antigen stimulation. Conveniently, the immune cells are lymphocytes and more particularly T-lymphocytes. 15 The immune effector molecules may be any of a range of molecules which are produced in response to cell activation or stimulation by an antigen. Although an interferon (IFN) such as IFN-y is a particularly useful immune effector molecule, others include a range of cytokines such as interleukins (IL), e.g. IL-2, IL-4, 1L-10 or IL-12, tumor necrosis factor 20 alpha (TNF-c), a colony stimulating factor (CSF) such as granulocyte (G)-CSF or granulocyte macrophage (GM)-CSF amongst many others such as complement or components in the complement pathway. Accordingly, in another preferred embodiment, the present invention provides a method 25 for measuring a CMI response in a subject, said method comprising collecting a sample from said:subject wherein said sample comprises cells of the inmune system which are capable of producing IFN-y molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an IFN-y molecule wherein the presence or level of said IFN-y molecule is indicative of the 30 capacity of said subject to mount a cell-mediated immune response.
WO 2004/042396 PCT/AU2003/001464 -9 As far as the preferred embodiment extends to humans is concerned, the present invention further provides a method for measuring a CMI response in a human subject, said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing IFN-y molecules following stimulation 5 by an antigen, incubating said sample with an antigen and then measuring the presence or elevation in level of an IFN-y molecule wherein the presence or level of said IFN-y molecule is indicative of the capacity of said human subject to mount a cell-mediated immune response. 10 The sample collected from the subject is generally deposited into a blood collection tube. A blood collection tube includes a blood draw tube or other similar vessel. Conveniently, when the sample is whole blood, the blood collection tube is heparinized. Alternatively, heparin is added to the tube after the blood is collected. Notwithstanding that whole blood is the preferred and most convenient sample, the present invention extends to other 15 samples containing immune cells such as lymph fluid, cerebral fluid, tissue fluid and respiratory fluid including nasal and pulmonary fluid. The use of blood collection tubes is compatible with standard automated laboratory systems and these are amenable to analysis in large-scale and random access sampling. 20 Blood collection tubes also minimize handling costs and reduce laboratory exposure to whole blood and plasma and, hence, reduce the risk of laboratory personnel from contracting a pathogenic agent such as HIV or hepatitis B virus (HBV). Combining the incubation step with the collection tube is particularly efficacious and 25 enhances the sensitivity of the assay as does the optional feature of incubating the cells in the presence of a sample sugar such as dextrose. The cells of the CMI system lose the capacity to mount a CMI response in whole blood after extended periods following blood draw from the subject, and responses without 30 intervention are often severely reduced or absent 24 hours following blood draw. The reduction of labor and need for specialized plasticware allows CMI stimulation with WO 2004/042396 PCT/AU2003/001464 -10 antigens to be performed at the point of care locations such as physicians' offices, clinics, outpatient facilities and veterinary clinics or on farms. Once antigen stimulation is complete, the requirement for fresh and active cells no longer exists. IFN-y and other cytokines or immune effector molecules are stable in plasma and, thus, the sample can be 5 stored, or shipped without special conditions or rapid time requirements in a similar fashion to standard serum samples used for other infectious disease or other disease diagnosis. The incubation step may be from 5 to 50 hours, more preferably 5 to 40 hours and even 10 more preferably 8 to 24 hours or a time period in between. Accordingly, another preferred embodiment of the present invention contemplates a method for measuring a CMI response in a subject including a human subject, said method comprising collecting a sample of whole blood from said subject, incubating said whole 15 blood sample with an antigen and then measuring the presence or elevation in level of an immune effector molecule such as IFN-y wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell-mediated immune response. 20 In one preferred embodiment, the incubation step is conducted in the presence of a simple sugar such as dextrose. The ability to measure CMI is important for assessing a subject's ability to respond to an infection by an pathogenic agent such as a microorganism or virus or parasite, to mount an 25 autoimmune response such as in diabetes or to protect against cancers or other oncological conditions. Consequently, reference to "measuring a CMI response in a subject" includes an encompasses immune diagnosis of infectious and autoinimmune diseases, a marker for immunocompetence and the detection of T-cell responses to endogenous and/or exogenous antigens (including a measure of the efficacy of a vaccine) as well as a marker for 30 inflammatory diseases and cancer.
WO 2004/042396 PCT/AU2003/001464 - 11 Autoimmune diseases contemplated herein include inter alia Alopecia Areata, Ankylosing Spondylitis, Antiphospholipid Syndrome, Autoimmune Addison's Disease Multiple Sclerosis, Autoimmune disease of the adrenal gland, Autoimmune Hemolytic Anemia, Autoimmune Hepatitis, Autoimmune oophoritis and orchitis, Behcet's Disease, Bullous 5 Pemphigoid, Cardiomyopathy, Celiac Sprue-Dermatitis, Chronic Fatigue Syndrome (CFIDS), Chronic Inflam. Demyelinating, Chronic Inflam. Polyneuropathy, Churg-Strauss Syndrome, Cicatricial Pemphigoid, CREST Syndrome, Cold Agglutinin Disease, Crohn's Disease, Dermatitis herpetiformis, Discoid Lupus, Essential Mixed Cryoglobulinemia, Fibromyalgia, Glomerulonephritis, Grave's Disease, Guillain-Barre, Hashimoto's 10 Thyroiditis, Idiopathic Pulmonary Fibrosis, Idiopathic Thrombocytopenia Purpura (ITP), IgA Nephropathy Insulin Dependent Diabetes (Type I), Lichen Planus, Lupus, Meniere's Disease, Mixed Connective Tissue Disease, Multiple sclerosis, Myasthenia Gravis, Myocarditis, Pemphigus Vulgaris, Pernicious Anemia, Polyarteritis Nodosa, Polychondritis, Polyglancular Syndromes, Polymyalgia Rheumatica, Polymyositis and 15 Dermatomyositis, Primary Agammaglobulinemia, Primary Biliary Cirrhosis, Psoriasis, Raynaud's Phenomenon, Reiter's Syndrome, Rheumatic Fever, Rheumatoid Arthritis, Sarcoidosis, Seleroderma, Sjogren's Syndrome, Stiff-Man Syndrome, Systemic lupus erythematosus, Takayasu Arteritis, Temporal Arteritis/Giant Cell Arteritis, Ulcerative Colitis, Uveitis, Vasculitis and Vitiligo. 20 It is generally important to assess the potential or actual CMI responsiveness in these individuals. Other disease conditions contemplated include inflammatory disease conditions. 25 Examples of inflammatory disease conditions contemplated by the present invention include but are not limited to those disease and disorders which result in a response of redness, swelling, pain, and a feeling of heat in certain areas that is meant to protect tissues affected by injury or disease. Inflammatory diseases which can be treated using the 30 methods of the present invention, include, without being limited to, acne, angina, arthritis, aspiration pneumonia, disease, empyema, gastroenteritis, inflammation, intestinal flu, WO 2004/042396 PCT/AU2003/001464 -12 NEC, necrotizing enterocolitis, pelvic inflammatory disease, pharyngitis, PID, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic 5 Inflammatory Demyelinating Polyradiculoneuropathy. Cancer therapy also is somewhat dependent on CMI. Cancers contemplated herein include: a group of diseases and disorders that are characterized by uncontrolled cellular growth (e.g. formation of tumor) without any differentiation of those cells into specialized 10 and different cells. Such diseases and disorders include ABL1 protooncogene, AIDS Related Cancers, Acoustic Neuroma, Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Adenocystic carcinoma, Adrenocortical Cancer, Agnogenic myeloid metaplasia, Alopecia, Alveolar soft-part sarcoma, Anal cancer, Angiosarcoma, Aplastic Anaemia, Astrocytoma, Ataxia-telangiectasia, Basal Cell Carcinoma (Skin), Bladder 15 Cancer, Bone Cancers, Bowel cancer, Brain Stem Glioma, Brain and CNS Tumours, Breast Cancer, CNS tumours, Carcinoid Tumours, Cervical Cancer, Childhood Brain Tumours, Childhood Cancer, Childhood Leukaemia, Childhood Soft Tissue Sarcoma, Chondrosarcoma, Choriocarcinoma, Chronic Lymphocytic Leukaemia, Chronic Myeloid Leukaemia, Colorectal Cancers, Cutaneous T-Cell Lymphoma, Dermatofibrosarcoma 20 protuberans, Desmoplastic-Small-Round-Cell-Tumour, Ductal Carcinoma, Endocrine Cancers, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing's Sarcoma, Extra Hepatic Bile Duct Cancer, Eye Cancer, Eye: Melanoma, Retinoblastoma, Fallopian Tube cancer, Fanconi Anaemia, Fibrosarcoma, Gall Bladder Cancer, Gastric Cancer, Gastrointestinal Cancers, Gastrointestinal-Carcinoid-Tumour, Genitourinary Cancers, 25 Germ Cell Tumours, Gestational-Trophoblastic-Disease, Glioma, Gynaecological Cancers, Haematological Malignancies, Hairy Cell Leukaemia, Head and Neck Cancer, Hepatocellular Cancer, Hereditary Breast Cancer, Histiocytosis, Hodgkin's Disease, Human Papillomavirus, Hydatidiform mole, Hypercalcemia, Hypopharynx Cancer, IntraOcular Melanoma, Islet cell cancer, Kaposi's sarcoma, Kidney Cancer, Langerhan's 30 Cell-Histiocytosis, Laryngeal Cancer, Leiomyosarcoma, Leukaemia, Li-Fraumeni Syndrome, Lip Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Lymphedema, WO 2004/042396 PCT/AU2003/001464 -13 Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Male Breast Cancer, Malignant-Rhabdoid-Tumour-of-Kidney, Medulloblastoma, Melanoma, Merkel Cell Cancer, Mesothelioma, Metastatic Cancer, Mouth Cancer, Multiple Endocrine Neoplasia, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloma, Myeloproliferative Disorders, 5 Nasal Cancer, Nasopharyngeal Cancer, Nephroblastoma, Neuroblastoma, Neurofibromatosis, Nijmegen Breakage Syndrome, Non-Melanoma Skin Cancer, Non Small-Cell-Lung-Cancer-(NSCLC), Ocular Cancers, Oesophageal Cancer, Oral cavity Cancer, Oropharynx Cancer, Osteosarcoma, Ostomy Ovarian Cancer, Pancreas Cancer, Paranasal Cancer, Parathyroid Cancer, Parotid Gland Cancer, Penile Cancer, Peripheral 10 Neuroectodennrmal-Tumours, Pituitary Cancer, Polycythemia vera, Prostate Cancer, Rare cancers-and-associated-disorders, Renal Cell Carcinoma, Retinoblastoma, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Salivary Gland Cancer, Sarcoma, Schwannoma, Sezary syndrome, Skin Cancer, Small Cell Lung Cancer (SCLC), Small Intestine Cancer, Soft Tissue Sarcoma, Spinal Cord Tumours, Squamous-Cell-Carcinoma 15 (skin), Stomach Cancer, Synovial sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer, Transitional-Cell-Cancer-(bladder), Transitional-Cell-Cancer-(renal-pelvis-/ ureter), Trophoblastic Cancer, Urethral Cancer, Urinary System Cancer, Uroplakins, Uterine sarcoma, Uterus Cancer, Vaginal Cancer, Vulva Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumour. 20 Any of a range of antigens may be tested such as those specific for a particular organism, virus, autoantigen or cancer cell. Alternatively, more general agents may be used to test generic capacity of a cell-mediated immune response. Examples of the latter include PPD from M. tuberculosis and tetanus toxoid. In general, however, any peptide, polypeptide or 25 protein, carbohydrate, glycoprotein, phospholipid, phosphoprotein or phospholipoprotein or non-protein chemical agent may be used in the assay system. As stated above, detection of the immune effector molecules may be made at the protein or nucleic acid levels. Consequently, reference to "presence or level of said immune effector 30 molecule" includes direct and indirect data. For example, high levels of IFN-y mRNA is indirect data showing increased levels of IFN-y.
WO 2004/042396 PCT/AU2003/001464 -14 Ligands to the immune effectors are particularly useful in detecting and/or quantitating these molecules. Antibodies to the immune effectors are particularly useful. Techniques for the assays contemplated herein are known in the art and include, for example, sandwich 5 assays, ELISA and ELISpot. Reference to "antibodies" includes parts of antibodies, mammalianized (e.g. humanized) antibodies, recombinant or synthetic antibodies and hybrid and single chain antibodies. Both polyclonal and monoclonal antibodies are obtainable by immunization with the 10 immune effectors or antigenic fragments thereof and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of the immune effector, or antigenic part thereof, collecting serum from the animal and isolating specific sera by any of the 15 known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product. The use of monoclonal antibodies in an immunoassay is particularly preferred because of 20 the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art. 25 Another aspect of the present invention contemplates, therefore, a method for detecting an immune effector in a sample comprising immune cells from a subject, said method comprising contacting said sample or an aliquot of said sample with an antibody specific for said immune effector or antigenic fragment thereof for a time and under conditions sufficient for an antibody-effector complex to form, and then detecting said complex. 30 WO 2004/042396 PCT/AU2003/001464 - 15 A sample includes whole blood. This method includes micro-arrays and macro-arrays on planar or spherical solid supports. A micro- or macro-array is useful. A wide range of immunoassay techniques are available as can be seen by reference to U.S. 5 Patent Nos. 4,016,043, 4,424,279 and 4,018,653. The following is a description of one type of assay. An unlabeled antibody is immobilized on a solid substrate and the sample to be tested for the immune effectors (e.g. antigens) brought into contact with the bound molecule. After a suitable period of incubation, for a 10 period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labeled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labeled antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by 15 the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of antigen. This generalized technique is well known to those skilled in the art as would be any of a number of variations. 20 In these assays, a first antibody having specificity for the instant immune effectors is either covalently or passively bound to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, spheres, discs of microplates, or any other surface suitable for conducting an 25 immunoassay. The binding processes are well known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-120 minutes or where more convenient, overnight) and under suitable conditions (e.g. for about 30 20 0 C to about 40 0 C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with WO 2004/042396 PCT/AU2003/001464 -16 a second antibody specific for a portion of the antigen. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to the hapten. 1 5 There are many variations to this assay. One particularly useful variation is a simultaneous assay where all or many of the components are admixed substantially simultaneously. By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection 10 of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules. Examples of suitable fluorophores are provided in Table 2. In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of 15 glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the 20 corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labeled antibody is added to the first antibody-antigen complex, allowed to bind, and then the excess reagent is washed away. A solution 25 containing the appropriate substrate is then added to the complex of antibody-antigen antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of antigen which was present in the sample. Again, the present invention extends to a substantially simultaneous assay. 30 WO 2004/042396 PCT/AU2003/001464 -17 Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by 5 emission of the light at a characteristic colour visually detectable with a light microscope. The fluorescent labeled antibody is allowed to bind to the first antibody-antigen complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the antigen of interest. Immunofluorescene and EIA techniques are both very well 10 established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. There are a range of other detection systems which may be employed including colloidal 15 gold and all such detection systems are encompassed by the present invention. The present invention also contemplates genetic assays such as involving PCR analysis to detect RNA expression products of a genetic sequence encoding an immune effector. 20 In one embodiment, PCR is conducted using pairs of primers, one or both of which are generally labeled with the same or a different reporter molecule capable of giving a distinguishable signal. The use of fluorophores is particularly useful in the practice of the present invention. Examples of suitable fluorophores may be selected from the list given in Table 2. Other labels include luminescence and phosphorescence as well as infrared dyes. 25 These dyes or fluorophores may also be used as reporter molecules for antibodies.
WO 2004/042396 PCT/AU2003/001464 - 18 TABLE 2 List of suitable fluorophores Probe Ex, (nm) Em (nm) Reactive and conjugated probes Hydroxycoumarin 325 386 Aminocoumarin 350 455 Methoxycoumarin 360 410 Cascade Blue 375; 400 423 Lucifer Yellow 425 528 NBD 466 539 R-Phycoerythrin (PE) 480; 565 578 PE-Cy5 conjugates 480; 565; 650 670 PE-Cy7 conjugates 480; 565; 743 767 APC-Cy7 conjugates 650; 755 767 Red 613 480; 565 613 Fluorescein 495 519 FluorX 494 520 BODIPY-FL 503 512 TRITC 547 574 X-Rhodamine 570 576 Lissamine Rhodamine B 570 590 PerCP 490 675 Texas Red 589 615 Allophycocyanin (APC) 650 660 TruRed 490, 675 695 Alexa Fluor 350 346 445 Alexa Fluor 430 430 545 Alexa Fluor 488 494 517 Alexa Fluor 532 530 555 Alexa Fluor 546 556 573 Alexa Fluor 555 556 573 Alexa Fluor 568 578 603 Alexa Fluor 594 590 617 Alexa Fluor 633 621 639 Alexa Fluor 647 650 688 Alexa Fluor 660 663 690 Alexa Fluor 680 679 702 Alexa Fluor 700 696 719 Alexa Fluor 750 752 779 Cy2 489 506 Cy3 (512); 550 570; (615) Cy3,5 581 596; (640) Cy5 (625); 650 670 Cy5,5 675 694 WO 2004/042396 PCT/AU2003/001464 -19 Probe Ex (nm) E 2 n m ) Cy7 743 767 -Nucleic acid probes _____________ Hoeschst 33342 343 483 DAPI -345 455 Hoechst 33258 345 478 SYTOX Blue 431 480 Chromomycin A3 445 575 Mithramycin 445 575 YOYO-1 491 509 SYTOX Green 504 523 SYTOX Orange 547 570 Ethidium Bormide 493 620 7-AAD 546 647 Acridine Orange 503 530/640 TOTO-1, TO-PRO-1 509 533 Thiazole Orange 510 530 Propidium Iodide (PI) 536 617 TOTO-3, TO-PRO-3 642 661 LDS 751 543; 590 712; 607 Fluorescent Proteins Y66F 360 508 Y66H 360 442 EBFP 380 440 Wild-type 396, 475 50,503 GFPuv 385 508 ECFP 434 477 Y66W 436 485 S65A 471 504 S65C 479 507 S65L 484 510 S65T 488 511 EGFP 489 508 EYFP 514 527 DsRed 558 583 Otherprobes Monochlorobimane 380 461 Calcein 496 517 S Ex: Peak excitation wavelength (nm) 2 Em: Peak emission wavelength (nm) WO 2004/042396 PCT/AU2003/001464 - 20 Any suitable method of analyzing fluorescence emission is encompassed by the present invention. In this regard, the invention contemplates techniques including but not restricted to 2-photon and 3-photon time resolved fluorescence spectroscopy as, for example, disclosed by Lakowicz et al., Biophys. J. 72: 567, 1997, fluorescence lifetime imaging as, 5 for example, disclosed by Eriksson et al., Biophys. J. 2: 64, 1993 and fluorescence resonance energy transfer as, for example, disclosed by Youvan et al., Biotechnology et elia 3: 1-18, 1997. Luminescence and phosphorescence may result respectively from a suitable luminescent or 10 phosphorescent label as is known in the art. Any optical means of identifying such label may be used in this regard. Infrared radiation may result from a suitable infrared dye. Exemplary infrared dyes that may be employed in the invention include but are not limited to those disclosed in Lewis et 15 al., Dyes Pigm. 42(2): 197, 1999, Tawa et al., Mater. Res. Soc. Symp. Proc. 488 [Electrical, Optical and Magnetic Properties of Organic Solid-State Materials IV], 885 890, Daneshvar et al., J Immunol. Methods 226(1-2): 119-128, 1999, Rapaport et al., Apple. Phys. Lett. 74(3): 329-331, 1999 and Durig et al., J. Raman Spectrosc. 24(5): 281 285, 1993. Any suitable infrared spectroscopic method may be employed to interrogate the 20 infrared dye. For instance, fourier transform infrared spectroscopy as, for example, described by Rahman et al., J Org. Chem. 63: 6196, 1998 maybe used in this regard. I Suitably, electromagnetic scattering may result from diffraction, reflection, polarization or refraction of the incident electromagnetic radiation including light and X-rays. Such 25 scattering can be used to quantitate the level of mRNA or level of protein. Flow cytometry is particularly useful in analyzing fluorophore emission. As is known in the art, flow cytometry is a high throughput technique which involves 30 rapidly analyzing the physical and chemical characteristics of particles (e.g. labeled rmRNA, DNA or proteins) as they pass through the path of one or more laser beams while WO 2004/042396 PCT/AU2003/001464 -21 suspended in a fluid stream. As each particle intercepts the laser beam, the scattered light and fluorescent light emitted by each cell or particle is detected and recorded using any suitable tracking algorithm as, for example, described hereunder. 5 A modem flow cytometer is able to perform these tasks up to 100,000 cells/particles s 1. Through the use of an optical array of filters and dichroic mirrors, different wavelengths of fluorescent light can be separated and simultaneously detected. In addition, a number of lasers with different excitation wavelengths may be used. Hence, a variety of fluorophores can be used to target and examine, for example, different immune effectors within a 10 sample or immune effectors from multiple subjects. Suitable flow cytometers which may be used in the methods of the present invention include those which measure five to nine optical parameters (see Table 3) using a single excitation laser, commonly an argon ion air-cooled laser operating at 15 mW on its 488 nm 15 spectral line. More advanced flow cytometers are capable of using multiple excitation lasers such as a HeNe laser (633 nm) or a HeCd laser (325 nm) in addition to the argon ion laser (488 or 514 nm). TABLE 3 Exemplary optical parameters which may be measured by a flow cytometer. 20 Parameter Acronym Detection angle form Wavelength incident laser beam (unm) Forward scattered light FS 2-50 488' Side scattered light SS 900 488* "Green" fluorescence FL1 900 510-540 "Yellow" fluorescence FL2 900 5 6 0
-
5 8 0 "Red" fluorescence FL3 900 >650" using a 488 nm excitation laser t width ofbandpass filter # longpass filter 25 WO 2004/042396 PCT/AU2003/001464 - 22 For example, Biggs et al., Cytometry 36.: 36-45, 1999 have constructed an 11-parameter flow cytometer using three excitation lasers and have demonstrated the use of nine distinguishable fluorophores in addition to forward and side scatter measurements for purposes of immunophenotyping (i.e. classifying) particles. The maximum number of 5 parameters commercially available currently is 17: forward scatter, side scatter and three excitation lasers each with five fluorescence detectors. Whether all of the parameters can be adequately used depends heavily on the extinction coefficients, quantum yields and amount of spectral overlap between all fluorophores (Malemed et al., "Flow cytomet y and sorting", 2 nd Ed., New York, Wiley-Liss, 1990). However, it will be understood that the 10 present invention is not restricted to any particular flow cytometer or any particular set of parameters. In this regard, the invention also contemplates use in place of a conventional flow cytometer, a microfabricated flow cytometer as, for example, disclosed by Fu et al., Nature Biotechnology 17: 1109-1111, 1999. 15 The assay of the present invention may be automated or semi-automated for high throughput screening or for screening for a number of immune effectors from the one subject. The automation is conveniently controlled by computer software. The present invention contemplates a computer program product, therefore, for assessing 20 the presence or absence or the level of one or more immune effectors, said product comprising: (1) code that receives, as input values, the identity of a reporter molecule associated with a labeled mRNA or antibody: 25 (2) code that compares said input values with reference values to determine the level of reporter molecules and/or the identity of the molecule to which the reporter molecule is attached; and 30 (3) a computer readable medium that stores the codes.
WO 2004/042396 PCT/AU2003/001464 -23 Still another aspect of the present invention extends to a computer for assessing the presence or absence or level of one or more immune effectors, said computer comprises: (1) a machine-readable data storage medium comprising a data storage material 5 encoded with machine-readable data, wherein said machine-readable data comprise input values which identify a reporter molecule associated with a labeled mRNA or antibody; (2) a working memory for storing instructions for processing said machine-readable 10 data; (3) a central-processing unit coupled to said working memory and to said machine readable data storage medium, for processing said machine readable data to compare said values to provide an assessment of the identity or level of reporter 15 molecules or of molecules to which they are attached; and (4) an output hardware coupled to said central processing unit, for receiving the results of the comparison. 20 A version of these embodiments is presented in Figure 1, which shows a system 10 including a computer 11 comprising a central processing unit ("CPU") 20, a working memory 22 which may be, e.g. RAM (random-access memory) or "core" memory, mass storage memory 24 (such as one or more disk drives or CD-ROM drives), one or more cathode-ray tube ("CRT") display terminals 26, one or more keyboards 28, one or more 25 input lines 30, and one or more output lines 40, all of which are interconnected by a conventional bidirectional system bus 50. Input hardware 36, coupled to computer 11 by input lines 30, may be implemented in a variety of ways. For example, machine-readable data of this invention may be inputted via 30 the use of a modem or modems 32 connected by a telephone line or dedicated data line 34. Alternatively or additionally, the input hardware 36 may comprise CD. Alternatively, WO 2004/042396 PCT/AU2003/001464 - 24 ROM drives or disk drives 24 in conjunction with display terminal 26, keyboard 28 may also be used as an input device. Output hardware 46, coupled to computer 11 by output lines 40, may similarly be 5 implemented by conventional devices. By way of example, output hardware 46 may include CRT display terminal 26 for displaying a synthetic polynucleotide sequence or a synthetic polypeptide sequence as described herein. Output hardware might also include a printer 42, so that hard copy output may be produced, or a disk drive 24, to store system output for later use. 10 In operation, CPU 20 coordinates the use of the various input and output devices 36,46 coordinates data accesses from mass storage 24 and accesses to and from working memory 22, and determines the sequence of data processing steps. A number of programs may be used to process the machine readable data of this invention. Exemplary programs may use, 15 for example, the following steps: (1) inputting input values which identifies a reporter molecule associated with a labeled mRNA or antibody; 20 (2) assessing including comparing said input values with reference values to determine the level of reporter molecule and/or the identity of the molecule to which the reporter molecule is attached; and (3) outputting the results of the assessment. 25 Figure 2 shows a cross section of a magnetic data storage medium 100 which can be encoded with machine readable data, or set of instructions, for assessing the level of an immune effector which can be carried out by a system such as system 10 of Figure 1. Medium 100 can be a conventional floppy diskette or hard disk, having a suitable substrate 30 101, which may be conventional, and a suitable coating 102, which may be conventional, on one or both sides, containing magnetic domains (not visible) whose polarity or WO 2004/042396 PCT/AU2003/001464 - 25 orientation can be altered magnetically. Medium 100 may also have an opening for receiving the spindle of a disk drive or other data storage device 24. The magnetic domains of coating 102 of medium 100 are polarized or oriented so as to encode in manner which may be conventional, machine readable data for execution by a system such as system 10 5 of Figure 1. Figure 3 shows a cross section of an optically readable data storage medium 110 which also can be encoded with such a machine-readable data, or set of instructions, for designing a synthetic molecule of the invention, which can be carried out by a system such 10 as system 10 of Figure 1. Medium 110 can be a conventional compact disk read only memory (CD-ROM) or a rewritable medium such as a magneto-optical disk, which is optically readable and magneto-optically writable. Medium 100 preferably has a suitable substrate 111, which may be conventional, and a suitable coating 112, which may be conventional, usually of one side of substrate 111. 15 In the case of CD-ROM, as is well known, coating 112 is reflective and is impressed with a plurality of pits 113 to encode the machine-readable data. The arrangement of pits is read by reflecting laser light off the surface of coating 112. A protective coating 114, which preferably is substantially transparent, is provided on top of coating 112. 20 The present invention further contemplates a kit for assessing a subject's capacity to mount a cell mediated response. The kit is conveniently in compartmental form with one or more compartments adapted to receive a sample from a subject such as whole blood. That compartment or another compartment may also be adapted to contain heparin where the 25 sample is whole blood with or without a simple sugar such as dextrose. The simple sugar may also be maintained in a separate container. Generally, the kit is in a form which is packaged for sale with a set of instructions. The instructions would generally be in the form of a method for measuring a CMI response in a 30 subject, said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing immune effector WO 2004/042396 PCT/AU2003/001464 - 26 molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence or elevation in level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell-mediated immune response. 5 The present invention further provides a method of treatment of a subject having a pathogenic infection, an autoimmune disorder or cancer or a propensity for developing such a disorder, said method comprising assessing the ability for said subject to mount a cell mediated immune response by the method of measuring a CMI response in a subject, 10 said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing immune effector molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the 15 capacity of said subject to mount a cell-mediated immune response and then selecting a suitable therapeutic protocol. The present invention is further described by the following non-limiting Examples.
WO 2004/042396 PCT/AU2003/001464 - 27 EXAMPLE 1 Development ofAssay Heparinized blood samples were collected from consenting volunteers or donors. Blood 5 samples were collected into Vacuette [registered trade mark] tubes (Greiner Bio-one, Germany). Aliquots of the blood samples were incubated with either Mycobacterium tuberculosis purified protein derivative (PPD, Cellestis Limited, Australia), Tetanus toxoid (CSL 10 Limited, Australia), phytohemagglutinin (Cellestis Limited, Australia) or saline control in a number of different sized blood collection tubes as well as the standard 24-well tissue culture plates recommended by the manufacturers of the bovine whole blood IFN-y test (Bovigam [registered trade mark], CSL Ltd.) or the human Quantiferon [registered trade mark] test (Cellestis Limited, Australia). 15 In some experiments, dextrose was added at various concentrations to the blood before initiation of incubation. Antigen stimulated blood samples were incubated for 16 to 24 hours at 37 0 C, after which 20 plasma was harvested from above the settled blood cells. The amount of IFN-y present in each plasma sample was then quantified using the Quantiferon-TB [registered trade] ELISA (Cellestis Limited, Australia) as per the manufacturer's instructions. Samples stimulated with the tetanus toxoid antigen and the saline control were also tested using a more sensitive ELISA for IFN-y (Quantiferon-CMI; Cellestis Limited, Australia) as per the 25 manufacturer's instructions. ELISA optical density values for IFN-y standards run on each ELISA plate were used to construct a standard curve from which the amount of IFN-y present in each of the test plasma samples was converted to IU/mL values.
WO 2004/042396 PCT/AU2003/001464 - 28 EXAMPLE 2 Evaluating the effect of adding dextrose to blood before culture with antigen Two blood samples were collected from volunteers and 8 x 1 mL aliquots added to 5 individual wells of a 24-well tissue culture plate. The four antigens provided with the Quantiferon-TB test, Saline control (Nil), M. tuberculosis PPD (Hu PPD), M. avium PPD (Av PPD) and phytohemagglutinin (Mitogen), were added to duplicate wells containing blood. To one set of the duplicate wells, dextrose was added to a final concentration of 2 mg/mL. The plates were shaken for 1 minute before incubation at 37 0 C for 20 hours in a 10 humidified atmosphere. Plasma samples were collected and the concentrations of IFN-7y were quantified using the Quantiferon-TB [registered trade] ELISA. The data demonstrate that the addition of dextrose to the blood, prior to incubation with antigen, resulted in an increase (1.4 to 2.2 fold) in the production of IFN-y when stimulated 15 with either of the PPD antigens (Table 4). In contrast, there was no increase in IFN-y detected with the addition of dextrose to blood stimulated with the saline negative control. For blood samples stimulated with Mitogen, there was a slight increase in IFN-y detected for one of the donors and a slight decrease for the other. 20 TABLE 4 Concentration of IFN-y in IU/mL found for each plasma sample. Blood had been stimulated with antigen either with or without dextrose at a concentration of 2 mg/mL. Stimulation antigen HuPPD AvPPD Mitogen Donor 1 -Dextrose 96.20 54.68 28.67 +Dextrose 142.25 76.50 25.71 Fold increase with dextrose 1.48 1.40 0.90 Donor 2 -Dextrose 71.34 31.55 108.72 +Dextrose 134.47 67.62 122.76 Fold increase with dextrose 1.88 2.14 1.13 25 WO 2004/042396 PCT/AU2003/001464 - 29 EXAMPLE 3 Determining the effect of incubating blood with antigen in a blood collection tube versus a 24-well tissue culture plate 5 Heparinized blood from 15 Blood Bank donors was dispensed (1 mL aliquots) into both 24-well plates and Vacuette [registered trade mark] tubes containing 125 jtL of HuPPD solution as supplied with the Quantiferon-TB [registered trade] kit. The 24-well plates were shaken for 1 minute and the capped Vacuette [registered trade mark] tubes mixed for 20 seconds by vortexing before incubation at 37 0 C for 20 hours in a humidified 10 atmosphere. The next day, plasma samples were collected from each incubation well and tube and the relative amounts of IFN-7y estimated using the Quantiferon-TB [registered trade] ELISA. Table 5 shows that for all blood samples there was an increase in the amount of IFN-y 15 detected for the samples that had been incubated in the blood collection tubes. This increase ranged from 1.1 times to 16.3 times the amount of IFN-y produced in the 24-well plate, with a mean increase of 4.7 times. Blood samples demonstrating smaller increases in IFN-y production were generally those demonstrating very low levels of response to the HuPPD. 20 WO 2004/042396 PCT/AU2003/001464 -30 TABLE 5 Amount of IFN-y detected from 1 mL blood samples incubated with HuPPD in either a 24-well tissue culture plate or a 2 mL blood collection tube Donor HuPPD HuPPD Fold increase 24-ell (control) Blood collection tube (Tube/24-well) 1 0.025* 0.044 1.8 2 0.056 0.765 13.7 3 0.230 0.852 3.7 4 0.069 0.428 6.2 5 0.034 0.058 1.7 6 0.084 0.135 1.6 7 1.196 0.725 3.7 8 0.030 0.215 7.2 9 0.087 1.422 16.3 10 0.032 0.057 1.8 11 0.029 0.032 1.1 12 0.037 0.138 3.7 13 0.036 0.057 1.6 14 0.067 0.121 1.8 15 0.292 0.213 4.2 Mean fold increase 4.7 5Optical density @ 450/620 n * Optical density @ 450/620 nim WO 2004/042396 PCT/AU2003/001464 -31 EXAMPLE 4 Effect of incubation of blood with antigens in blood collection tubes - 2 Twenty heparinized blood samples were collected from blood bank donors and 3 x 1 mL aliquots were dispensed into individual wells of a 24-well tissue culture tray. To the 5 respective wells, 125 tL of Saline, HuPPD or Mitogen were added. After shaking, the culture trays were incubated for 20 hours at 37 0 C in a humidified atmosphere, before harvesting of plasma samples. One mL aliquots of blood were also added to duplicate Vacuette [registered trade mark] 10 tubes (Greiner Bio-one, Germany), which had previously had the same antigens as above added. The capped tubes were then mixed for 20 seconds using a vortex mixer and incubated for 20 hours at 37 0 C, before harvesting of plasma samples. All plasma samples were tested for IFN-y content using the standard Quantiferon-TB 15 [registered trade mark] ELISA system. Threshold of detection was 2 IU/mL in this ELISA system. The data in Table 6 show that for blood samples stimulated with human PPD, there was an increase in IFN-y detected when the blood incubations had been performed in a blood 20 collection tube rather than the 24-well tissue culture plate. For 5 of the 20 donor blood samples there was negligible response to the PPD antigen in either tissue culture plate or blood collection tube. For the remaining 15 blood samples, 12 demonstrated an increase in IFN-y production with the in-tube incubation, one did not alter, and two showed a decrease. 25 In contrast to the results for the protein antigen HuPPD, incubation of blood in the blood collection tubes in the presence of the mitogen phytohemagglutinin generally resulted in lower levels of IFN-y production than seen for the same samples incubated in 24-well plates. Such a difference may be expected due to the different mechanism of T-cell 30 stimulation induced by the directly acting mitogen as compared to the immune mechanism stimulated by antigen/antigen presenting cell/T-cell interaction.
WO 2004/042396 PCT/AU2003/001464 - 32 TABLE 6 Amount of IFN-y detected from 1 mL blood samples incubated with HuPPD or mitogen in either a 24-well tissue culture plate or a blood collection tubes 5 Donor Human Hunan Tube/24- Mitogen, Mitogen Tube/24 PPD 24- PPD Tube well 24-well Tube well well 1 *3.32 1.79 NA 7.69 3.52 0.46 2 52.52 93.05 1.77 83.34 61.94 0.74 3 20.46 51.87 2.54 1.13 13.13 NA 4 2.02 7.72 3.82 10.04 7.95 0.79 5 71.19 120.82 1.70 6.85 3.45 0.05 6 3.55 4.11 1.16 12.32 13.32 1.08 7 0.00 0.09 NA 8.77 5.29 0.60 8 3.05 4.61 1.51 76.98 68.58 0.89 9 22.55 54.33 2.41 65.02 47.53 0.73 10 21.79 13.06 0.60 8.14 5.80 0.71 11 5.86 13.47 2.30 -0.56 -0.79 NA 12 3.63 6.53 1.80 21.79 16.34 0.75 13 28.62 28.77 1.01 30.58 22.52 0.74 14 2.67 10.52 3.93 28.26 19.16 0.68 15 0.43 0.51 NA 8.10 5.71 0.71 16 39.90 118.11 2.96 2.75 1.88 NA 17 7.57 4.47 0.59 6.14 3.55 0.58 18 1.77 1.91 NA 14.05 9.07 0.65 19 2.59 5.63 2.17 2.46 7.91 3.22 20 0.68 0.27 NA 11.80 8.73 0.74 Mean fold increase 2.02 Mean fold increase 0.73 NA Not applicable as IFN-y detected was less than 2 IU/mL for either 24-well plate or tube. * Concentration of IFN-y in IU/mL after subtraction of the value of the respective 10 saline negative control. + Mean result from duplicate tubes.
WO 2004/042396 PCT/AU2003/001464 -33 Table 7 shows the ELISA optical density values (450/620 nm) for the saline control samples from both the 24-well and in-tube incubations. The data show that there was no increase in the negative control values when blood was incubated in the blood collection tubes. Therefore, as there is an increase in the amount of IFN-y produced in response to 5 HuPPD and no increase in background IFN-y responses, the signal to noise ratio for the in tube incubation is significantly higher than that seen for the standard 24-well incubation method. TABLE 7 Background of IFN-y responses (OD @ 450/620 nm) from 1 mL blood 10 samples incubated with saline in either a 24-well tissue culture plate or a L blood collection tube and tested using the Quantiferon-TB [registered trade mark] ELISA Donor 24-well Tube A Tube B Tube Mean 24-well Tube Mean 1 0.024 0.023 0.027 0.025 -0.001 2 0.02 0.02 0.023 0.022 -0.002 3 0.033 0.024 0.025 0.025 0.009 4 0.026 0.026 0.023 0.025 0.002 5 0.021 0.021 0.022 0.022 0.000 6 0.069 0.063 0.060 0.062 0.008 7 0.024 0.022 0.023 0.023 0.002 8 0.023 0.025 0.039 0.032 -0.009 9 0.021 0.021 0.021 0.021 0.000 10 0.021 0.024 0.021 0.023 -0.002 11 0.022 0.026 ND 0.026 -0.004 12 0.023 0.024 0.022 0.023 0.000 13 0.017 0.018 0.017 0.018 -0.001 14 0.018 0.021 0.021 0.021 -0.003 15 0.019 0.020 ND 0.020 -0.001 16 0.017 0.016 0.021 0.019 -0.002 17 0.017 0.015 0.016 0.016 0.002 18 0.02 0.018 0.018 0.018 0.002 19 0.02 0.019 0.021 0.020 0.000 20 0.018 0.020 0.018 0.019 -0.001 Mean OD for 24-well minus tube 0.000 WO 2004/042396 PCT/AU2003/001464 - 34 EXAMPLE 5 Effect of incubation of blood with tetanus toxoid in blood collection tubes, with and without dextrose 5 Twenty heparinized blood samples were collected from blood bank donors and 3 x 1 mL aliquots were dispensed into individual wells of a 24-well tissue culture tray. To the respective wells, 125 tL of Saline, Tetanus toxoid, or Tetanus toxoid + dextrose were added. After mixing, the culture trays were incubated for 20 hours at 37 0 C in a humidified atmosphere, before harvesting of plasma samples. 10 One mL aliquots of blood were also added to duplicate Vacuette [registered trade mark] tubes (Greiner Bio-one, Germany), which had previously had the same antigens as above added. The capped tubes were then mixed for 20 seconds using a vortex mixer and incubated for 20 hours at 37oC, before harvesting of plasma samples. 15 Samples from blood that had been stimulated with the saline control, tetanus toxoid, and tetanus toxoid with dextrose were tested using the sensitive Quantiferon-CMI ELISA which has a threshold of detection of 0.05 IU/mL. The results demonstrate that an average 4.5-fold increase in the amount of IFN-y detected, above that for the saline control, was 20 found for blood that had been incubated with tetanus toxoid in the blood collection tubes, as compared with the 24-well tissue culture tray (Table 8). Moreover, results from the tubes containing tetanus toxoid and dextrose demonstrated a greater than 7.8-fold increase in IFN-y production over the 24-well tray (Table 8).
WO 2004/042396 PCT/AU2003/001464 -35 TABLE 8 Amount of IFN-y detected (IU/mL) from 1 mL blood samples incubated with tetanus toxoid with or without dextrose added in either a 24-well tissue culture plate or a blood collection tube TetTox TetTox+Dextrose Donor 24-well Tube Tube + Dextrose Tube/24 well Tube/24 well 1 1.58 1.34 7.15 0.85 4.53 2 12.345 22.15 23.29 1.79 1.89 3 0.118 0.38 0.55 3.22 4.64 4 0.406 4.20 3.04 10.34 7.50 5 0.38 2.85 5.26 7.50 13.84 6 13.66 17.96 20.80 1.31 1.52 7 0.406 1.86 1.98 4.59 4.87 8 0.337 1.10 3.25 3.26 9.65 9 26.488 29.92 28.69 1.13 1.08 10 0.074 0.10 0.35 1.28 4.68 11 0.015 0.11 0.09 7.40 5.67 12 0.843 4.43 12.56 5.26 14.90 13 1.703 9.15 20.91 5.37 12.28 14 0.777 6.46 3.45 8.31 4.44 15 0.258 2.31 8.75 8.96 33.92 16 5.528 28.08 27.13 5.08 4.91 17 0.092 0.09 0.18 1.00 1.94 18 0.323 2.05 5.14 6.35 15.92 19 4.162 28.39 29.22 6.82 7.02 20 3.587 1.54 5.50 0.43 1.53 Mean fold increase 4.51 7.84 5 Table 9 shows the amount of IFN-7 detected (IU/mL) for the saline control samples from both the 24-well and in-tube incubations when tested using the sensitive IFN-y ELISA. The data shows that there was a slight decrease in the negative control values when blood was 10 incubated in the blood collection tubes. Therefore, as there is an increase in the amount of IFN-y produced in response to tetanus toxoid and a slight decrease in background IFN-y responses, the signal to noise ratio for the in-tube incubation is significantly higher than that seen for the standard 24-well incubation method.
WO 2004/042396 PCT/AU2003/001464 -36 TABLE 9 Background IFN-y responses (IU/mL) from 1 mL blood samples incubated with saline in either a 24-well tissue culture plate or a blood collection tube and tested using a sensitive IFN-y ELISA Donor 24-well Tube A Tube B Tube Mean 24-well - Tube Mean 1 0.166 0.137 0.137 0.137 0.029 2 0.039 0.038 0.028 0.033 0.006 3 0.044 0.010 0.016 0.013 0.031 4 0.030 0.025 0.028 0.027 0.004 5 0.029 0.024 0.024 0.024 0.005 6 0.571 0.539 0.568 0.554 0.018 7 0.030 0.029 0.029 0.029 0.001 8 0.044 0.020 0.017 0.019 0.026 9 0.085 0.067 0.067 0.067 0.018 10 0.041 0.030 0.032 0.031 0.010 11 0.026 0.030 ND 0.026 0.000 12 0.024 0.026 0.022 0.024 0.000 13 0.043 0.032 0.032 0.032 0.011 14 0.036 0.032 0.036 0.034 0.002 15 0.034 0.030 ND 0.015 0.019 16 0.045 0.034 0.038 0.036 0.009 17 0.043 0.034 0.036 0.035 0.008 18 0.038 0.043 0.043 0.043 -0.005 19 0.045 0.031 0.027 0.029 0.016 20 0.074 0.029 0.036 0.033 0.042 Mean OD for 24-well minus tube 0.012 5 To test the effect of adding dextrose to the saline negative control blood incubation wells, blood from 9 of the 20 donors was cultured with the saline control and with and without dextrose in 24-well plates. The data show that there was no significant difference in 10 background levels of IFN-y detected when dextrose was added to the saline control stimulated blood samples (Table 10).
WO 2004/042396 PCT/AU2003/001464 -37 TABLE 10 Background IFN-y responses (OD @ 450/620 nM) from blood samples incubated with saline in 24-well tissue culture plates with or without dextrose and tested using a using a sensitive IFN-y ELISA 5 Donor 24-well 24-well + Dextrose 2 0.035 0.036 7 0.029 0.028 12 0.016 0.019 13 0.025 0.022 14 0.022 0.021 16 0.026 0.032 17 0.024 0.017 19 0.025 0.019 20 0.036 0.025 EXAMPLE 6 10 Comparison of In-Tube vs Culture Plate Stimulation The assay of the present invention quantifies IFN-y generated as a CMI response to the stimulation of whole blood with test antigens. Stimulation of 1 mL volumes of blood with a panel of negative control (Nil), positive control (Mitogen) and test antigens is performed 15 in a 24-well culture plate. The "In-Tube" stimulation culture method is an alternate technology developed for use in the assay system. This method employs the addition of either Nil, Mitogen or test stimulation antigens to heparinized blood collection tubes for the purpose of initiating 20 blood stimulation immediately upon the drawing of a 1 mL blood sample. Dextrose is also added to the tubes in order to enhance IFN-y response. This experiment aimed to compare the two blood culture methods, the culture plate versus the in-tube. 25 WO 2004/042396 PCT/AU2003/001464 -38 Heparinized blood from patients diagnosed with Tuberculosis was stimulated in 24-well culture plate (Coming - Costar) with Nil (negative control), Mitogen (phytohaemagluttinin; positive control) and TB-specific antigens (overlapping peptides for ESAT-6, CFP-10 and a 25 mer section of TB7.7). Blood was also collected into 3 blood collection tubes 5 (Greiner) with the same Nil, PHA, and TB-specific antigens in the tubes, along with heparin. The blood samples were incubated for 16 to 24 hours at 37 0 C before harvesting plasma from above the settled blood cells. Plasma samples were tested to determine the IFN-y concentration using ELISA and in some cases TB ELISA (if the specific antigen response was >15 IU/mL). 10 The culture plate and in-tube results from 10 patents were compared. Nil values were subtracted from each of the TB-Specific Antigen responses. The patent's "Mitogen minus Nil" result of "Specific Antigen minus Nil" result had to be >0.5 1U/mL for the data to be considered valid (as per the product insert for TB ELISA). The results are shown in Table 15 11. TABLE 11 Comparison of Culture Plate and Blood Collection Tube (In-Tube) whole blood stimulation Subject Culture Plate Method In-Tube Method Culture In-Tube Fold Plate Change of Specific antigen (In-Tube vs Plate) Nil Specific Mitogen Nil Specific Mitogen Specific Specific Antigens Antigens Antigens Antigens -Nil - Nil 1 0.18 282.90 128.70 1.30 424.90 52.50 282.72 423.60 1.50 2 0.10 2.46 15.182* 0.29 7.55 4.15 2.36 7.27 3.08 3 0.12 1.01 17.017* 0.20 5.51 17.377* 0.89 5.31 5.99 4 0.09 2.72 6.52 0.08 5.95 5.57 2.64 5.88 2.23 5 0.07 2.96 8.25 0.06 3.89 2.31 2.89 3.83 1.32 6 0.07 5.04 19.76* 0.09 10.31 11.77 4.98 10.21 2.05 7 0.30 1.34 19.868* 0.46 4.14 21.063* 1.05 3.68 3.52 8 1.22 2.05 11.11 0.61 1.81 4.02 0.83 1.21 1.44 9 0.09 1.22 14.66 0.16 2.17 11.23 1.13 2.01 1.78 10 0.11 4.26 12.65 0.62 9.27 17.05* 4.15 8.65 2.08 Mean 2.50 20 *OD outside the range of the plate reader WO 2004/042396 PCT/AU2003/001464 -39 The data indicate that an increased IFN-y response is obtained using the In-Tube system compared to the current culture plate method (mean fold change = 2.50). 5 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or 10 more of said steps or features.
WO 2004/042396 PCT/AU2003/001464 - 40 BIBLIOGRAPY Biggs et al., Cytometry 36: 36-45, 1999. Daneshvar et al., J. Immunol. Methods 226(1-2): 119-128, 1999. Durig et al., J Raman Spectrosc. 24(5): 281-285, 1993. Eriksson et al., Biophys. J. 2: 64, 1993. Fu et al., Nature Biotechnology 17: 1109-1111, 1999. Lakowicz et al., Biophys. J 72: 567, 1997. Lewis et al., Dyes Pigm. 42(2): 197, 1999. Malemed et al., "Flow cytometry and sorting", 2 nd Ed., New York, Wiley-Liss, 1990). Rahman et al., J. Org. Chem. 63: 6196, 1998. Rapaport et al., Appl. Phys. Lett. 74(3): 329-331, 1999. Tawa et al., Mater. Res. Soc. Symp. Proc. 488 [Electrical, Optical and Magnetic Properties of Organic Solid-State Materials IV], 885-890. Youvan et al., Biotechnology et elia 3: 1-18, 1997.
Claims (72)
1. A method for measuring a CMI response in a subject, said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing immune effector molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell mediated immune response.
2. The method of Claim 1 wherein the subject is a human.
3. The method of Claim 1 or 2 wherein the sample is whole blood.
4. The method of Claim 3 wherein the whole blood is collected in a tube comprising antigen.
5. The method of Claim 3 wherein the whole blood is collected in a tube comprising heparin.
6. The method of Claim 4 wherein the title further comprises heparin.
7. The method of Claim 1 wherein the sample is incubated with the antigen for from about 5 to about 50 hours.
8. The method of Claim 3 wherein the whole blood is incubated with antigen for from about 5 to about 50 hours.
9. The method of Claim 1 wherein the immune effector molecule is a cytokine.
10. The method of Claim 9 wherein the cytokine is IFN-y. WO 2004/042396 PCT/AU2003/001464 - 42
11. The method of Claim 9 wherein the cytokine is GM-CSF.
12. The method of Claim 9 wherein the cytokine is an interleukin.
13. The method of Claim 9 wherein the cytokine is a TNFx.
14. The method of Claim 1 or 2 wherein the subject is infected by a pathogenic agent.
15. The method of Claim 14 wherein the pathogenic agent is HBV.
16. The method of Claim 14 wherein the pathogenic agent is HIV.
17. The method of Claim 1 wherein the immune cells are selected from NK cells, T-cells, B-cells, dendritic cells, macrophages or monocytes.
18. The method of Claim 17 wherein the immune cells are T-cells.
19. The method of Claim 7 or 8 wherein the incubation occurs in the presence of a simple sugar.
20. The method of Claim 19 wherein the simple sugar is dextrose.
21. The method of Claim 1 wherein the antigen is a peptide.
22. The method of Claim 1 wherein the antigen is a polypeptide.
23. The method of Claim 1 wherein the antigen is a protein.
24. The method of Claim 1 wherein the antigen is a glycoprotein.
25. The method of Claim 1 wherein the antigen is a carbohydrate. WO 2004/042396 PCT/AU2003/001464 -43
26. The method of Claim 1 wherein the antigen is selected from a phospholipid, phosphoprotein and a phospholipoprotein.
27. The method of Claim 1 wherein the antigen is a TB-specific antigen.
28. The method of Claim 27 wherein the TB-specific antigen is an overlapping peptide for ESAT-6.
29. The method of Claim 27 wherein the TB-specific antigen is an overlapping peptide for CFP- 10.
30. The method of Claim 27 wherein the TB-specific antigen is an overlapping peptide for TB7.
31. The method of Claim 1 wherein the antigen is PPD from Mycobacterium tuberculosis.
32. The method of Claim 1 wherein the antigen is PPD from Mycobacterium avium.
33. The method of Claim 1 wherein the antigen is phytohemagglutinin.
34. The method of Claim 1 wherein the antigen is tetanus toxoid.
35. The method of Claim 1 wherein the immune effectors are detected with antibodies specific for same.
36. The method of Claim 35 wherein the immune effectors are detected using ELISA.
37. The method of Claim 45 wherein the immune effectors are detected using ELISpot. WO 2004/042396 PCT/AU2003/001464 -44
38. A method of treatment of a subject having a pathogenic infection, an autoimmune disorder or cancer or a propensity for developing such a disorder, said method comprising assessing the ability for said subject to mount a cell mediated immune response by the method of measuring a CMI response in a subject, said method comprising collecting a sample from said subject wherein said sample comprises cells of the immune system which are capable of producing immune effector molecules following stimulation by an antigen, incubating said sample with an antigen and then measuring the presence of or elevation in the level of an immune effector molecule wherein the presence or level of said immune effector molecule is indicative of the capacity of said subject to mount a cell-mediated immune response and then selecting a suitable therapeutic protocol.
39. The method of Claim 38 wherein the subject is a human.
40. The method of Claim 38 or 39 wherein the sample is whole blood.
41. The method of Claim 40 wherein the whole blood is collected in a tube comprising antigen.
42. The method of Claim 40 wherein the whole blood is collected in a tube comprising heparin.
43. The method of Claim 41 wherein the title further comprises heparin.
44. The method of Claim 38 wherein the sample is incubated with the antigen for from about 5 to about 50 hours.
45. The method of Claim 40 wherein the whole blood is incubated with antigen for from about 5 to about 50 hours.
46. The method of Claim 38 wherein the immune effector molecule is a cytokine. WO 2004/042396 PCT/AU2003/001464 - 45
47. The method of Claim 46 wherein the cytokine is IFN-y.
48. The method of Claim 46 wherein the cytokine is GM-CSF.
49. The method of Claim 46 wherein the cytokine is an interleukin.
50. The method of Claim 46 wherein the cytokine is a TNFc.
51. The method of Claim 38 wherein the immune cells are selected from NK cells, T-cells, B-cells, dendritic cells, macrophages or monocytes.
52. The method of Claim 51 wherein the immune cells are T-cells.
53. The method of Claim 44 or 45 wherein the incubation occurs in the presence of a simple sugar.
54. The method of Claim 53 wherein the simple sugar is dextrose.
55. The method of Claim 38 wherein the antigen is selected from a peptide.
56. The method of Claim 38 wherein the antigen is selected from a polypeptide.
57. The method of Claim 38 wherein the antigen is selected from a protein.
58. The method of Claim 38 wherein the antigen is selected from a glycoprotein.
59. The method of Claim 38 wherein the antigen is selected from a carbohydrate.
60. The method of Claim 38 wherein the antigen is selected from a phospholipid, phosphoprotein and phospholipoprotein. WO 2004/042396 PCT/AU2003/001464 - 46
61. The method of Claim 38 wherein the antigen is a TB-specific antigen.
62. The method of Claim 61 wherein the TB-specific antigen is an overlapping peptide for ESAT-6.
63. The method of Claim 61 wherein the TB-specific antigen is an overlapping peptide for CFP-10.
64. The method of Claim 61 wherein the TB-specific antigen is an overlapping peptide for TB7.
65. The method of Claim 38 wherein the antigen is PPD from Mycobacterium tuberculosis.
66. The method of Claim 38 wherein the antigen is PPD for Mycobacterium avium.
67. The method of Claim 38 wherein the antigen is phytohemagglutinin.
68. The method of Claim 38 wherein the antigen is tetanus toxoid.
69. The method of Claim 38 wherein the immune effectors are detected with antibodies specific for same.
70. The method of Claim 69 wherein the immune effectors are detected using ELISA.
71. The method of Claim 70 wherein the immune effectors are detected using ELISpot. WO 2004/042396 PCT/AU2003/001464 -47
72. A kit for measuring a CMI response in a subject said kit being in multicomponent form wherein a first component comprises a multiplicity of blood collection tubes, a second component comprises an antibody-based detection means for an immune effector molecule and a third component comprises a set of instructions which instructions comprise the following: (i) collect blood in the blood collection tubes; (ii) mix the tubes; (iii) incubate the tubes upright; (iv) centrifuge the tubes and collect the plasma; and (v) detect immune effector molecules in plasma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003277989A AU2003277989B2 (en) | 2002-11-08 | 2003-11-06 | Diagnostic assay for measuring a cell mediated immune response |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002952548 | 2002-11-08 | ||
AU2002952548A AU2002952548A0 (en) | 2002-11-08 | 2002-11-08 | Diagnostic assay |
PCT/AU2003/001464 WO2004042396A1 (en) | 2002-11-08 | 2003-11-06 | Diagnostic assay for measuring a cell mediated immune response |
AU2003277989A AU2003277989B2 (en) | 2002-11-08 | 2003-11-06 | Diagnostic assay for measuring a cell mediated immune response |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003277989A1 true AU2003277989A1 (en) | 2004-06-07 |
AU2003277989B2 AU2003277989B2 (en) | 2010-04-22 |
Family
ID=34314495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003277989A Expired AU2003277989B2 (en) | 2002-11-08 | 2003-11-06 | Diagnostic assay for measuring a cell mediated immune response |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2003277989B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2977053B1 (en) | 2008-11-30 | 2017-07-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
WO2015038624A1 (en) | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
AU2015323979A1 (en) | 2014-09-29 | 2017-05-18 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
-
2003
- 2003-11-06 AU AU2003277989A patent/AU2003277989B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
AU2003277989B2 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7608392B2 (en) | Diagnostic assay for measuring a cell mediated immune response | |
US8871508B2 (en) | Cell-mediated immune response assay and kits therefor | |
EP2310850B1 (en) | A diagnostic method | |
CA2840484C (en) | A cell mediated immune response assay with enhanced sensitivity | |
EP2577307B1 (en) | A diagnostic assay | |
AU2003277989B2 (en) | Diagnostic assay for measuring a cell mediated immune response | |
EP2702165B1 (en) | An assay of cell mediated immune responsiveness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
PC | Assignment registered |
Owner name: QIAGEN AUSTRALIA HOLDING PTY. LTD. Free format text: FORMER OWNER(S): CELLESTIS LIMITED |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |